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ABSTRACT
Bluetongue virus (BTV) is the causative agent of bluetongue, a major infectious disease of ruminants with serious consequences
to both animal health and the economy. The clinical outcome of BTV infection is highly variable and dependent on a variety of
factors related to both the virus and the host. In this study, we show that the BTV nonstructural protein NS4 favors viral replica-
tion in sheep, the animal species most affected by bluetongue. In addition, NS4 confers a replication advantage on the virus in
interferon (IFN)-competent primary sheep endothelial cells and immortalized cell lines. We determined that in cells infected
with an NS4 deletion mutant (BTV8NS4), there is increased synthesis of type I IFN compared to cells infected with wild-type
BTV-8. In addition, using RNA sequencing (RNA-seq), we show that NS4modulates the host IFN response and downregulates
mRNA levels of type I IFN and interferon-stimulated genes. Moreover, using reporter assays and protein synthesis
assays, we show that NS4 downregulates the activities of a variety of promoters, such as the cytomegalovirus immediate-early
promoter, the IFN- promoter, and a promoter containing interferon-stimulated response elements (ISRE). We also show that
the NS4 inhibitory activity on gene expression is related to its nucleolar localization. Furthermore, NS4 does not affect mRNA
splicing or cellular translation. The data obtained in this study strongly suggest that BTVNS4 is an IFN antagonist and a key de-
terminant of viral virulence.
IMPORTANCE
Bluetongue is one of the main infectious diseases of ruminants and is caused by bluetongue virus (BTV), an arthropod-borne
virus transmitted from infected to susceptible animals by Culicoides biting midges. Bluetongue has a variable clinical outcome
that can be related to both virus and host factors. It is therefore critical to understand the interplay between BTV and the host
immune responses. In this study, we show that a nonstructural protein of BTV (NS4) is critical to counteract the innate immune
response of the host. Infection of cells with a BTVmutant lacking NS4 results in increased synthesis of IFN- and upregulation
of interferon-stimulated genes. In addition, we show that NS4 is a virulence factor for BTV by favoring viral replication in sheep,
the animal species most susceptible to bluetongue.
Bluetongue virus (BTV) is the causative agent of bluetongue, amajor infectious disease of ruminants with serious conse-
quences for both animal health and the economy (1). Throughout
the 20th century, bluetongue occurred almost exclusively in trop-
ical and subtropical geographical areas (2). However, in the last 2
decades, the geographical limits of the disease have expanded, and
BTV is now endemic in more temperate areas, such as southern
and central Europe (3).
BTV is an arbovirus transmitted byCulicoides sp. bitingmidges
and belongs to the genus Orbivirus within the Reoviridae (4, 5).
The BTV genome consists of 10 double-stranded RNA (dsRNA)
genome segments encoding seven structural and four, possibly
five, nonstructural proteins (6–9). The core particle, formed by
VP3 and VP7, encapsidates the viral genome segments, each asso-
ciatedwith a replicase complex comprising VP1, VP4, andVP6 (6,
10–12). VP2 and VP5 constitute the outer capsid of the BTV vi-
rion and are responsible for cell attachment and entry (13–15).
VP2 is the most variable BTV protein and determines the virus
serotype, 27 of which have been described to date (16–19).
The BTV nonstructural proteins play fundamental roles in vi-
rus replication. NS1 forms tubules in the cytoplasm of BTV-in-
fected cells and favors viral protein synthesis (20–22). NS2 is the
major component of viral inclusion bodies (23–25), while NS3/
NS3A play a critical role in virus intracellular trafficking and
egress (26, 27). NS3 has also been shown to downregulate tran-
scription from the beta interferon (IFN-) promoter in reporter
assays (28). A putative fifth nonstructural protein may be ex-
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pressed from a conserved small open reading frame (ORF) in seg-
ment 10 (29).
NS4 is a small protein (77 to 79 amino acid residues) encoded
by an ORF in genome segment 9 overlapping the larger ORF en-
coding VP6 and with nucleolar localization. Although NS4 has
been shown to confer a replication advantage on BTV in cells
treated with interferon, it is dispensable for BTV replication in
IFN-incompetent cell lines and has no impact on pathogenicity in
IFN-/ receptor/ (IFNAR/) mice (8, 9).
The clinical outcome of BTV infection is highly variable and
dependent upon a variety of viral, host, and, likely, environmental
factors (30–35). Understanding the interplay between BTV and
the host immune response will be central to identifying the virus
and host determinants of disease susceptibility.
In order to establish a successful infection, BTV must over-
come both physical and innate immune barriers. One of the key
innate immunemechanisms for fighting viral infections is the IFN
system (36). Mammalian cells possess pattern recognition recep-
tors that detect incoming pathogen signatures and induce the syn-
thesis and secretion of IFN-. Secreted IFN signals in both auto-
crine and paracrine fashions, leading to the transcription of
hundreds of IFN-stimulated genes (ISGs), some of which have a
direct or indirect antiviral effect (37). BTV is known to induce an
IFN response, both in vitro and in vivo, and consequently, it must
possess countermeasures that allow the virus to replicate in the
face of this host response (8, 38–43). Evidence to date suggests that
BTVNS3 andNS4 are the viral proteinsmost likely responsible for
the disruption of the cellular innate immune response to BTV
infection (8, 28).
In this study, we investigated the interaction of BTV and the
IFN response of the host. We demonstrate that NS4 is an impor-
tant virulence factor in sheep, a natural host of BTV infection, and
acts as an interferon antagonist.
MATERIALS AND METHODS
Cell cultures.Vero, BHK21, and BSR (a clone of BHK21, kindly provided
by Karl K. Conzelmann) (44) cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum
(FBS). CPT-Tert cells are sheep choroid plexus cells immortalized with
the simian virus 40 (SV40) T antigen andhuman telomerase reverse trans-
criptase (hTERT) (45). CPT-Tert cells were grown in Iscove’s modified
Dulbecco’smedium (IMDM) supplementedwith 10%FBS. A549 cells are
derived from a human lung adenocarcinoma and were grown in DMEM
supplemented with 10% FBS. All cell lines were cultured at 37°C in a 5%
CO2 humidified atmosphere.
Primary ovine endothelial cells (ovEC) were obtained as previously
described (46). ovEC were seeded in 12-well plates and maintained in a
low-oxygen incubator (37°C, 5% CO2, and 3% O2). In this study, ovEC
were passaged once before being used and cultured at 37°C in a 5% CO2
humidified atmosphere.
Viruses. Wild-type BTV8 (BTV8wt) and an NS4 deletion mutant
(BTV8NS4) used in this study were obtained by reverse genetics as de-
scribed previously (8, 47). Virus stock titers were determined by standard
plaque assays using CPT-Tert cells (48). The defective-interfering (DI)-
rich preparation of Sendai virus (SeV) (Cantell strain) was generated by
sequentially passaging the virus at a high multiplicity of infection (MOI),
as previously described (49). Encephalomyocarditis virus (EMCV) was
used in interferon protection assays (see below) and was prepared as pre-
viously described (50).
Virus replication curves.Replication curves were carried out in either
ovEC or A549 cells. The cells were infected with the appropriate virus
(MOI  0.01), and the supernatants were collected at 24, 48, and 72 h
postinfection (p.i.). The supernatants were subsequently titrated by end-
point dilution analysis on BSR cells using the method of Reed and
Muench and expressed as log10 50% tissue culture infective doses
(TCID50)/ml (51). Each experiment was performed independently in
triplicate using at least two different stocks of each virus.
Ethical statement. All animal experimental procedures carried out in
this study were approved by the ethical committee of the Istituto Zoopro-
filattico Sperimentale dell’Abruzzo e Molise G. Caporale (Teramo, Italy)
(protocol no. 11427/2012) and further approved by the ItalianMinistry of
Health (Ministero della Salute) in accordance with Council Directive 86/
609/EEC of the European Union and the Italian D.Igs 116/92.
In vivo pathogenicity studies. Experiments were carried out using 15
sheep (Italianmixed breed) in an insect-proof isolation unit. Before inoc-
ulation, all the animals were confirmed to have no antibodies against BTV
using a blocking enzyme-linked immunosorbent assay (ELISA) as previ-
ously described (52). The absence of BTV genome in blood samples from
each animal was also confirmed by quantitative reverse transcription-
PCR (qRT-PCR) as described previously (30). The animals (n  5 per
group) were infected with 5 ml of either BTV8wt or BTV8NS4 (2 106
PFU in total) by multiple intradermal inoculations in the inner leg and
prescapular areas. Negative controls were inoculated with 5 ml of mock-
infected cell supernatants. Body temperature was recorded daily, begin-
ning a week before inoculation, until day 14 p.i. and subsequently at days
17, 21, and 28. Fever was defined as a rectal temperature above 40°C.
EDTA blood samples were collected daily from all the animals for 14 days
p.i. and thereafter at days 17, 21, and 28, when the experiment was termi-
nated. The blood samples were analyzed for the presence of viremia by
qRT-PCR as previously described (30). Sera were collected from each
animal on the day of the inoculation (day 0) and then at days 7, 14, 21, and
28 p.i. The presence in infected sheep of neutralizing antibodies against
BTV8 was assessed by virus neutralization assay as previously described
(53).
Plasmids and antisera. The open reading frame encoding NS4 was
either amplified by PCR [BTV8 NET2006/04 (GenBank accession
number JX680455), BTV1 RSArrrr/01 (JX680465), and BTV-2IT(L)
(JN255870)] or synthesized commercially (Genscript) [(BTV-2RSA(WT)
(JN255930), BTV-9IT(L) (JN255910), BTV1SASEG9 (D10905), BTV25
(EU839845), and BTV26 (JN255161)] and cloned into the pCI mamma-
lian expression vector (Promega). BTV10 segment 8 (NC_006007) was
synthesized commercially (Genscript) and cloned into pCI. All plasmids
used in this study were sequenced before use. Plasmid pCMV-luc was
obtained by inserting the firefly luciferase (FLuc) open reading frame into
pCDNA3.1 (Invitrogen) as previously described (54). pRL-CMV (Pro-
mega) is similar to pCMV-luc but contains an intron before the Renilla
luciferase (RLuc) gene. p125Luc expresses FLuc under the control of the
IFN- promoter (55). pISRE-Luc (Promega) contains five copies of the
interferon-stimulated response element (ISRE)-binding sequence (56) lo-
cated upstream of the TATA-like promoter region from the herpes sim-
plex virus thymidine kinase (HSV-TK) promoter.
Antisera used in this study included polyclonal rabbit antisera raised
against the BTV NS4 and NS2 proteins, as previously described (8). An-
tibodies against B23 (Sigma), -tubulin (Sigma), IRF-3 (clone FL-425;
Santa Cruz), and NF-B p65 (clone D14E12; Cell Signaling) were ob-
tained commercially.
In vitro RNA transcription.Capped and polyadenylated RNA for use
in luciferase assayswas generated using themMessagemMachineT7Ultra
kit as recommended by the manufacturer’s instructions (Ambion), using
linearized pCMV-luc or pRL-CMV as a template.
An RNA control (named EU-Luc-pA) for use in transcriptome se-
quencing (RNA-seq) and qRT-PCR experiments was obtained as follows.
Linearized pCMV-luc was transcribed using the Megascript T7 kit (Am-
bion, Life Technologies) according to the manufacturer’s instructions,
with the exception that the transcription reaction mixture was supple-
mented with an analogue of uridine (5-ethynyl uridine [EU]; Invitrogen,
Life Technologies). The RNA was then polyadenylated following the
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poly(A) tailing procedure of the mMessage mMachine T7 Ultra kit. All in
vitro-transcribed RNA was recovered using the RNeasy minikit (Qiagen).
Labeling and extraction of nascent RNA for transcriptomic analy-
ses.A549 cells were seeded in 6-well plates, incubated at 37°C for 24 h, and
mock infected or infected with BTV8wt or BTV8NS4 at anMOI of 4. At
8, 12, and 16 h p.i., nascent RNA was labeled with 0.4 mM EU for 90 min.
The cells were lysed with 1 ml of TRIzol spiked with 1 ng of EU-Luc-
pA. Total RNA was then extracted using the TRIzol method and fur-
ther purified using RNeasy mini spin columns (Qiagen), including an
on-column DNase I digestion step (Qiagen), according to the manu-
facturer’s protocol.
RNA-seq. Total RNA (4.5 	g) was enriched by selectively depleting
rRNA using the RiboMinus Eukaryote kit v2 (Ambion, Life Technolo-
gies). The EU-labeled RNA was specifically linked to azide-modified bio-
tin by a chemical reaction and then captured on streptavidin magnetic
beads using the Click-iT Nascent RNA Capture kit (Molecular Probes,
Life Technologies). Biotin-labeled RNA (attached to the magnetic beads)
was fragmented and subsequently used to construct libraries using the Ion
Total RNA-seq kit v2 (Life Technologies) as described by the manufac-
turer. The amplified libraries were size selected using the E-Gel size select
system (Life Technologies) and assessed using a Tapestation (Agilent).
The libraries were quantified using theQubit HS dsDNA assay (Life Tech-
nologies) and sequenced using the Ion Proton sequencer (Life Technolo-
gies). The sequence reads were processed according to the Tuxedo pipe-
line (57). The read quality was first assessed using FastQC (58). Tophat2
and Bowtie2 were used to map short reads against the Homo sapiens ge-
nome (genome browser UCSC hg19), and a list of differentially expressed
genes was generated using CuffDiff2 (genes with Benjamini Hochberg P
values of0.05 were considered significant) (59, 60). Canonical pathway
analysis was performed using the Ingenuity Pathway Analysis (IPA) soft-
ware (Qiagen) by submitting the differentially expressed (DE) gene data
sets (see Tables S1 to S3 in the supplemental material) and using the
default parameters.
qRT-PCR. For qRT-PCR analysis, mRNA was purified from the total
RNA fraction using the DynabeadsmRNADirect kit (Ambion, Life Tech-
nologies) according to the manufacturer’s instructions before capturing
EU-labeled RNA, as described above. RNA captured on the streptavidin
beads was used directly as a template for cDNA synthesis using the Super-
Script Vilo cDNA synthesis kit (Invitrogen, Life Technologies). qPCRwas
performed using Brilliant III Ultra Fast QPCR master mix (Agilent) to
detect a selection of ISGs and housekeeping genes and the spiked EU-Luc-
pA. The sequences of primers and probes are available upon request.
Samples were run on an Mx3005P (Stratagene) PCR machine and ana-
lyzed using MxPro software (Stratagene). Mock-infected cells were used
as a calibrator against which the infected cells were compared. The
EU-Luc-pA RNA was used as an exogenous control to normalize the
results.
FIG 1 Experimental infection of sheep with BTV8wt and BTV8NS4. Three groups of sheep (n  5 per group) were mock infected or infected with either
BTV8wt or BTV8NS4. (Top) Body temperatures (average per group) of experimentally infected sheep. The rectal temperature of sheep is normally between
38.3 and 39.9°C (horizontal lines). (Middle) BTV RNA in blood samples of experimentally infected sheep. Viral RNAwas detected by qRT-PCR targeting Seg-5,
and the values are expressed as log10 copy number per microgram of total RNA. (Bottom) Box-and-whisker plot representing neutralizing antibodies in
experimentally infected sheep at 7, 14, 21, and 28 days postinfection as described in Materials and Methods. PD50, 50% protective dose. **, P
 0.01; ***, P

0.001 (two-way analysis of variance [ANOVA]; Bonferroni posttests) (gray stars, mock infected versus BTV8wt infected; black stars, BTV8wt infected versus
BTV8NS4 infected). The error bars represent standard deviations.
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Interferon protection assays. Interferon protection assays were per-
formed as previously described (46). Briefly, ovEC were first seeded in
12-well plates and incubated for 2 days. The cells were thenmock infected
or infected with the indicated virus at an MOI of 4, and the medium was
collected 16 h postinfection. Cell culture supernatants were treated with
UV light to inactivate any virus. CPT-Tert cells were incubatedwith 2-fold
dilutions of themedium for 24 h before infecting themwith EMCV for 72
h. The level of IFN (expressed as international units [IU]) was calculated
by monitoring wells that were protected from cell death induced by
EMCV and comparing them to known amounts of universal type I IFN
alpha (UIFN; PBL Assay Science).
Western blotting. Protein expression was assessed from total cell ly-
sates by sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) andWestern blotting using the various antisera indicated above as
previously described (61). For quantitativeWestern blotting, primary an-
tibodies were detected using fluorescently labeled secondary antibodies
(DyLight; Thermo Scientific) in a LI-COR Odyssey scanner. Bands were
quantified with the Odyssey software (LI-COR Biosciences).
Metabolic radiolabeling. ovEC were mock infected or infected with
BTV8wt or BTV8NS4 at anMOI of 4. At the time points indicated, cells
were incubated at 37°C for 30 min in medium lacking methionine. Nas-
cent proteins were labeled for 2 h with [35S]methionine/cysteine (0.8
MBq/ml; PerkinElmer), after which theywere resuspended in sample buf-
fer (60 mM Tris-HCl [pH 6.8], 2% SDS, 10% glycerol, 2.5% -mercap-
toethanol, 0.01% bromophenol blue), and the proteins were separated by
SDS-PAGE as described above. Visualization of labeled proteins was
achieved by exposure to a Storm 840 PhosphorImager (Molecular Dy-
namics) or to X-ray film. Band intensities were determined using Im-
ageQuant software (Amersham).
Luciferase assays. CPT-Tert cells grown in 24-well plates were
cotransfected using Lipofectamine 2000 (Invitrogen) with 100 ng of
pCMV-luc or pRL-CMV, along with 100 to 400 ng of the indicated pCI
plasmids expressing NS4. A similar procedure was performed to cotrans-
fect 200 ng of in vitro-transcribed RNA expressing firefly luciferase (see
above) and the appropriate expression plasmids, as indicated (100 to 400
ng).When using p125Luc (50 ng) and pISRE-luc (400 ng), 293T cells were
either infected with DI-rich preparations of SeV or treated with 200 U/ml
UIFN (PBL InterferonSource) 4 h posttransfection before incubating for a
further 18 h.
The total amount of plasmid DNA transfected was 500 ng for all ex-
periments, using the empty pCI plasmid to balance each transfection.
Luciferase activity was detected 22 h posttransfection, using a luciferase or
dual-luciferase assay system (Promega) as described by themanufacturer.
The percentage of luciferase was determined by setting the luciferase ac-
tivity or luminescence (expressed as relative light units [RLU]) detected in
control cells (i.e., transfected with pCMV-luc and an empty pCI plasmid
only) as 100%. Constitutive promoters could not be used as transfection
controls, as NS4 affects gene expression. However, each experiment was
repeated independently at least three times, with each sample assessed in
triplicate. For each experiment, at least two independent plasmid prepa-
rations were used. Relative lights units for each sample were always at least
100-fold above background. In addition, in some experiments, 5 ng of in
vitro-transcribed RNA encoding Renilla luciferase was used as an addi-
tional internal control.
Confocal microscopy. Experiments were performed using CPT-Tert
or A549 cells cultured in two-well glass chamber slides (Lab-Tek; Nalge
Nunc International). The cells were either transfected with the appropri-
ate plasmids or infected with the indicated viruses (MOI 4) for 16 to 22
h. The cells were washed with phosphate-buffered saline (PBS) and fixed
with 5% formaldehyde for 15 min. The fixed cells were then processed as
described previously (62) and incubated with the appropriate antisera.
Secondary antibodies were conjugated with either Alexa Fluor 488 or
Alexa Fluor 594 (Invitrogen, Molecular Probes). Slides were mounted
using Vectashield mounting medium with DAPI (4=,6-diamidino-2-phe-
nylindole) (Vector Laboratories). The slides were analyzed and images
were collected using a Leica TCS SP2 confocal microscope.
Nucleotide sequence accession number.RNA-seq data have been de-
posited in the European Nucleotide Archive (ENA) and can be accessed
through the study accession number PRJEB13366.
RESULTS
BTV8NS4 is attenuated in experimentally infected sheep. In a
previous study, we showed that a BTV8 NS4 deletion mutant
FIG 2 NS4 modulates IFN synthesis in infected cells. (A) In vitro replication
kinetics of BTV8wt and BTV8NS4 in primary ovEC and human A549 cells.
The cells were infectedwith BTV8wt (red) andBTV8NS4 (blue) at anMOI of
0.01, and the supernatants were titrated at the indicated time points as de-
scribed in Materials and Methods. Experiments were performed indepen-
dently three times. Two-way ANOVA, P 
 0.01. *, P 
 0.05; **, P 
 0.01
(Bonferroni posttests). (B) Upregulation of IFN- synthesis in BTV8-infected
cells (IFN protection assay). Primary ovEC were mock infected or infected
with the indicated viruses (MOI 4). Supernatants were then collected at 16 h
p.i. and inactivated by UV treatment, and the amount of IFN released in the
supernatants was determined in biological assays as described inMaterials and
Methods. The error bars represent standard deviations. One-way ANOVA,
P 0.002. ***, P
 0.001 (Tukey’s multiple-comparison test).
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(BTV8NS4) is as virulent as BTV8wt in experimental mouse
models of infection (8). Here, we wanted to determine whether
NS4 influenced virulence in sheep, the natural host of BTV infec-
tion. Therefore, we experimentally infected sheepwith BTV8wt or
BTV8NS4. Sheep infected with BTV8wt showed an elevation of
body temperature from day 6 to day 8 p.i. (Fig. 1, top). BTV RNA
was detectable at day 4 p.i. and reached a plateau from days 6 to 10
p.i., followed by a slow decrease. Viremia remained detectable
until the end of the experiment. In contrast, animals infected by
BTV8NS4 did not develop pyrexia and displayed a delayed onset
and lower levels of viremia. BTV RNA was below the detection
level in 4 of the 5 inoculated sheep at 4 weeks p.i., when the exper-
iment was stopped (Fig. 1,middle). Between days 4 and 28 p.i., the
average levels of BTV RNAwere between 102- and 105-fold higher
in sheep infected with BTV8wt than in those infected with
BTV8NS4. As expected, all BTV-infected animals developed
neutralizing antibodies from day 7 p.i. (Fig. 1, bottom). Alto-
gether, these data show that BTV8NS4 is attenuated in sheep and
suggest that NS4 is a virulence factor in vivo.
Replication kinetics of BTV8wt and BTV8NS4 in primary
ovine endothelial cells and humanA549 cells.We showed previ-
ously that BTV8NS4 replicates as efficiently as BTV8wt in im-
mortalized cell lines, such as hamster BSR and sheep CPT-Tert
cells (8), but these cell lines do not possess an intact IFN response
to viral infections (44, 45). Hence, we compared the replication
kinetics of BTV8wt and BTV8NS4 in primary ovEC. BTV8wt
reached titers approximately 20-fold higher than those of
BTV8NS4 at 72 h p.i. (Fig. 2A). Similarly, BTV8wt reached titers
nearly 60-fold higher than those of BTV8NS4 in the IFN-com-
petent human cell line A549 (Fig. 2A). These data demonstrate
that the presence of NS4 confers a replication advantage on BTV8
in cells that are capable of mounting an antiviral response.
NS4 inhibits IFN release, but not virus sensing, in infected
cells. Given the data obtained as described above and the previ-
ously published observation that NS4 confers a replication advan-
tage on BTV in cells pretreated with IFN (8), we next sought to
determinewhetherNS4 impacted the level of IFN released into the
supernatant of infected cells. Primary ovEC were infected at an
MOI of 4 with either BTV8wt or BTV8NS4. At 16 h p.i., the level
of IFN in the cell culture medium was measured using an IFN
protection assay. BTV8NS4-infected cells had, on average, 13
times more IFN (P
 0.001) in their supernatants than BTV8wt-
infected cells (Fig. 2B).
These results could potentially be explained by NS4 affecting
either the sensing of viral infection or transcription and/or the
synthesis/secretion of IFN into the supernatant. The first step in
IFN- expression is the recognition of pathogen-associated mo-
lecular patterns (PAMPs) by various host pattern recognition re-
ceptors, which results in the translocation of the transcription
factors IRF-3 and NF-B into the nucleus (37). In order to deter-
mine whether NS4 impacted supernatant levels of IFN by inter-
fering with this process, we infected A549 cells at an MOI of 4 for
16 h and assessed the nuclear translocation of IRF-3 andNF-Bby
confocal microscopy. The cellular localization of IRF-3 and
NF-B inmock-infected cells was exclusively cytoplasmic (Fig. 3),
while stimulation with tumor necrosis factor alfa (TNF-) used as
a positive control resulted in nuclear translocation of NF-B in
essentially 100% of the cells (not shown). In contrast, between 25
and 35% of cells infected by BTV8wt showed translocation of
IRF-3 and NF-B into the nucleus. BTV8NS4 was found to in-
duce levels of translocation similar to those of BTV8wt, suggesting
that NS4 does not prevent either PAMP recognition by the host
cells or translocation of IRF-3 and NF-B. NS2 immunolabeling
FIG 3 IRF-3 and NF-B nuclear translocation in BTV-infected cells. A549 cells were infected at an MOI of 4 for 16 h and fixed before being processed for
immunofluorescence using antibodies against NS2, IRF-3, andNF-Bwith an Alexa Fluor 488 secondary antibody (green). Nuclei were stained with DAPI
(blue). Average values (standard deviations) corresponding to the percentage of translocation are indicated for each experimental condition. Scale bars,
47.62 	m.
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confirmed similar levels of infection in cells infected with BTV8wt
or BTV8NS4 (Fig. 3).
NS4 downregulates IFN- and ISG mRNA levels. Next, we
carried out RNA-seq analysis of IFN-competent A549 cells in-
fected with either BTV8wt or BTV8NS4 in order to further char-
acterize the activity of NS4.Mock-infected A549 cells were used as
negative controls. Libraries were prepared from nascent RNA
metabolically labeled with a uracil analogue for 90 min at 12 h p.i.
(Fig. 4A) and sequenced on an Ion Proton sequencer (Life Tech-
nologies, Thermo Fisher). On average, 64.58 million reads per
sample were generated (Phred quality  20). We found 2,863
differentially expressed genes in cells infected by BTV8wt com-
pared to mock-infected cells, of which 1,055 were downregulated
and 1,808 were upregulated (Fig. 4B). In comparison, fewer genes
(n  2,292) were found to be differentially expressed in cells in-
fected by BTV8NS4 than in mock-infected cells, with 752 of
them being downregulated and 1,540 upregulated. The entire list
of differentially expressed genes in BTV8wt and BTV8NS4-in-
fected cells is presented in Tables S1 to S3 in the supplemental
material. The CH25H gene (encoding cholesterol 25-hydroxylase;
a known interferon-stimulated gene [ISG]) was found to be the
most upregulated gene in BTV8NS4-infected cells. A total of 117
genes were upregulated in BTV8NS4-infected cells compared to
BTV8wt-infected cells (see Table S3 in the supplemental mate-
FIG 4 RNA-seq of BTV8wt-, BTV8NS4-, andmock-infected cells. (A) Schematic representation of RNA-sequencing workflow. A549 cells were mock infected
or infected with BTV8wt or BTV8NS4 at an MOI of 4. At 12 h p.i., nascent RNA was metabolically labeled with an analogue of uridine (EU) at 0.4 mM for 90
min. Total RNA was extracted and enriched by selectively depleting rRNA transcripts. The EU-labeled RNA was chemically linked to azide-modified biotin and
then captured on streptavidin magnetic beads. Biotin-labeled RNA attached to the magnetic beads was used directly to construct a library and subsequently
sequenced using the Ion Proton sequencer. Sequence reads were processed as described inMaterials andMethods. (B) Plots representing DE genes according to
their fold change values. Log2-fold changes of1 were regarded as upregulated (q value [false-discovery rate]
 0.05), whereas changes of
1 were regarded as
statistically downregulated (q value
 0.05). (C) Validation of RNA-seq by qRT-PCR. mRNA levels of ACTB, ANXA1, TBP, B2M, IFN- (IFNB1), and IFIT1
were measured by qRT-PCR at 8 and 16 h p.i. as described in Materials and Methods. *, P 
 0.05; **, P 
 0.01; ***, P 
 0.001 (one-way ANOVA; Tukey’s
multiple-comparison test). The error bars represent standard deviations.
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rial). Of these 117 genes, 102 were either IFN genes or ISGs, ac-
cording to the Interferomedatabase (63). IFN-, IFN-1, IFN-2,
and IFN-3 genes were among the top 6 upregulated genes in
BTV8NS4-infected cells (87- to 136-fold more than in mock-
infected cells) (Table 1). Interestingly, more genes were strongly
upregulated (fold change  32) in BTV8NS4 (n  33) than in
BTV8wt-infected cells (n 7). These genes includedMX1 and -2;
interferon-induced protein with tetratricopeptide repeats 1
(IFIT1), -2, and -3; and OASL genes and other well-characterized
ISGs. However, all 33 of the genes highly upregulated in
BTV8NS4-infected cells were also upregulated (albeit at a lower
level) in BTV8wt-infected cells (Table 1). The IFN- gene, for
example, was also upregulated (17-fold) in BTV8wt-infected cells.
No major differences in the levels of expression in BTV8wt- and
BTV8NS4-infected cells were observed for the genes with the
highest levels of downregulation (Table 2). We validated the
RNA-seq analysis by qRT-PCR on selected genes found to be
equally or differentially expressed in mock-infected and infected
cells. RelativemRNA levels of IFNB1, IFIT1, beta-2microglobulin
(B2M), -actin (ACTB), annexin A1 (ANXA1), and TATA-bind-
ing protein (TBP) determined by RT-qPCR reflected the patterns
of expression observed in the RNA-seq analyses (Fig. 4C). The
Ingenuity Pathway Analysis software (Qiagen) was used to com-
pare the representation of canonical pathways between infected
and uninfected cells (Fig. 5A and B) and cells infected with either
BTV-8wt or BTV8NS4 (Fig. 5C). Most of the pathways were
involved in the cellular immune response, cytokine signaling, the
inflammatory response, apoptosis, and pathogen-related signal-
ing. Consistent with the RNA-seq data set, pathways relating to
the innate immune response were particularly evident when com-
paring BTV8NS4 with BTV8wt (Fig. 5C).
The availability of the transcriptome of cells infected by
BTV8wt and BTV8NS4 also provided additional information
regarding the possible influence of NS4 on mRNA maturation.
Comparable proportions of reads containing intron sequences
were found in mock-infected cells and in cells infected with
BTV8wt or BTV8NS4 (data not shown). In addition, we also
quantified how many reads finished with 8 or more adenines,
assuming these reads to be representative of polyadenylated
mRNAs. Comparable percentages of poly(A) reads were obtained
under the three conditions tested, suggesting that NS4 was not
associated with a global defect in mRNA polyadenylation (data
not shown).
NS4 modulates the activities of a wide range of promoters.
We next assessed the ability of BTV-8 NS4 to reduce the activities
of basal promoters, such as the cytomegalovirus (CMV) immedi-
ate-early promoter and the promoters of genes involved in the
host innate immune response (IFN- and ISRE-containing pro-
moters). 293T cells were cotransfected with a plasmid expressing
TABLE 1 Top 33 upregulated genes in BTV-infected compared to
mock-infected A549 cells
Gene
BTV8NS4 vs. mock
infected
BTV8wt vs. mock
infected
Ranka Fold change Rank Fold change
CH25H U1 142.3 U18 23.6
IFNB1 U2 136.4 U41 17.5
IFNL1 U3 105.6 U11 28.8
IFNL2 U4 91.0 U68 14.1
MX1 U5 88.6 U38 17.8
IFNL3 U6 87.7 U98 12.0
OASL U7 87.6 U13 28.3
IFIT2 U8 84.7 U14 25.9
RSAD2 U9 78.7 U50 16.3
IFIT1 U10 75.9 U36 18.2
CXCL11 U11 71.6 U24 21.5
IFIT3 U12 71.0 U40 17.6
CMPK2 U13 64.1 U112 11.2
IFI44 U14 63.4 U25 21.4
MX2 U15 61.8 U76 13.6
CCR4 U16 56.3 U17 24.0
IFI27 U17 49.7 U170 8.9
DDX58 U18 48.4 U115 11.0
OAS2 U19 46.1 U5 33.6
IFIH1 U20 45.5 U22 21.9
CA1 U21 45.0 U9 30.9
ISG15 U22 43.7 U78 13.4
FOSB U23 43.6 U3 35.0
EGR2 U24 42.5 U8 31.8
FOS U25 39.9 U15 25.3
IL-8 U26 39.3 U29 19.8
KLRC2 U27 36.8 U10 29.0
EGR1 U28 36.1 U6 32.9
SLC1A3 U29 35.9 U46 16.7
EGR4 U30 35.7 U59 14.9
BATF2 U31 33.5 U548 4.3
HERC5 U32 32.4 U69 14.0
IFI6 U33 32.3 U303 6.2
a Ranks of upregulated genes. The number (U1, U2, etc.) refers to the rank of the
specified gene. For example, the CH25H gene is the gene found to be the most
upregulated in BTV8NS4-infected cells compared to mock-infected cells.
TABLE 2 Top 20 downregulated genes in BTV-infected compared to
mock-infected A549 cells
Gene
BTV8NS4 vs. mock
infected
BTV8wt vs. mock
infected
Ranka Fold change Rank Fold change
CLDND2 D1 0.13 D157 0.30
CPN1 D2 0.13 D24 0.20
DHRS4L1 D3 0.14 D425 0.38
EMID1 D4 0.14 NAb 1.0
LOC100506229 D5 0.16 D3 0.15
HMOX1 D6 0.16 D4 0.15
KRT82 D7 0.16 D73 0.26
SHH D8 0.17 D5 0.15
NUPR1 D9 0.18 D11 0.18
KRT4 D10 0.18 D142 0.30
SFRP4 D11 0.19 D9 0.17
NRTN D12 0.19 NA 1.0
EMILIN1 D13 0.20 D18 0.20
LOC113230 D14 0.20 NA 1.0
LINC00086 D15 0.20 D329 0.36
OSGIN1 D16 0.21 D10 0.18
KLHDC7A D17 0.21 D1 0.12
ATOH8 D18 0.22 D2 0.14
MIR210HG D19 0.22 D106 0.28
KRTAP4-1 D20 0.22 D27 0.21
a Ranks of downregulated genes. The numbers D1, D2, etc. refer to the rank of the
specified gene (the most downregulated gene under a given condition is ranked first).
b NA, not applicable, as the genes were not found to be differentially expressed in the
samples considered.
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either BTV NS4 or NS2 and an FLuc reporter plasmid driven by
either the CMV promoter, the IFN- promoter, or a promoter
containing ISRE elements (Fig. 5). At 4 h posttransfection, cells
transfected with the IFN- promoter were stimulated with Sendai
virus, while cells transfected with the ISRE-containing promoter
were stimulated with universal IFN (200 U/ml). NS4, unlike NS2,
was able to reduce by between 40 and 60% the activities of CMV,
IFN-, and ISRE promoters (Fig. 6).
To further investigate the ability of NS4 to block host gene
expression, sheep cells were cotransfectedwith an expression plas-
mid for FLuc, under the control of the CMV immediate-early
promoter, along with a variety of expression plasmids expressing
BTVNS4 or an empty plasmid (also containing aCMVpromoter)
as a control (Fig. 7). NS4 is well conserved among the BTV sero-
types/strains identified to date (8). The only exceptions were a
strain of BTV-1 (GenBank accession number D10905, submitted
in 1992) and the more divergent BTV-25 and BTV-26 strains
(GenBank accession numbers EU839845 and JN255161), which
showed only 77.9%, 76.6%, and 75.3% identity to BTV-8 NS4,
respectively (Fig. 7A). All of the NS4 proteins tested were able to
reduce FLuc expression, with the notable exception of NS4 from
BTV-1 (D10905) (Fig. 7B). Interestingly, theNS4 protein of BTV-1
(D10905) displayed a mobility different from those of other NS4
proteins by SDS-PAGE that could be explained by the presence of
FIG 5 Cellular pathways of BTV8wt- and BTV8NS4-infected cells. (A to C) Canonical cellular pathways were analyzed using Ingenuity Pathway Analysis. Only
canonical pathways with a P value of 
6.3  105 are shown. The ratios correspond to the number of genes found DE in a given pathway divided by the total
number of genes contained in that pathway. A specific pathway is colored in orange or blue depending on whether it has been predicted to be activated (positive
Z-scores) or inhibited (negative Z-scores), respectively. The gray bars represent pathways where no prediction can currently be made. PRR, pattern recognition
receptors; AII, antiviral innate immunity; DC, dendritic dell; M, macrophages; EC, endothelial cells; RA, rheumatoid arthritis; GC, gastric cells; NKC, natural
killer cells; AR, antiviral response; OSR, oxidative-stress response; DM, diabetes mellitus. (A) BTV8NS4- versus mock-infected cells. (B) BTV8wt- versus
mock-infected cells. (C) BTV8NS4- versus BTV8wt-infected cells.
FIG 6 Effects of NS4 on expression driven by various promoters. CPT-Tert
cells were cotransfected with 100 ng of a DNA plasmid expressing either
BTV10 NS2 (GenBank accession number NC006007) or BTV8 NS4 and a
DNA plasmid expressing FLuc under the control of either the CMV (50 ng),
IFN- (50 ng), or ISRE (400 ng) promoter. After transfection (4 h), cells
transfected with the IFN- promoter were stimulated with Sendai virus, while
cells transfected with ISRE-containing promoter were stimulated with univer-
sal IFN. FLuc activitywas assessed 22 h posttransfection in a luminometer. Five
nanograms of capped and polyadenylated RNA made in vitro were also
cotransfected as a control for transfection efficiency. One-way ANOVA, P 
0.0002 (CMV), P 0.0015 (IFN-), and P 0.0006 (ISRE). **, P
 0.01; ***,
P
 0.001 (Dunnett’s multiple-comparison test).
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considerable differences in the basic residues in theN terminus. In
addition, using BTV-8 NS4, we showed that gene expression in-
hibition by NS4 was dose dependent (Fig. 7C).
Inaprevious study,weshowedthatNS4 localizes in thenucleoliof
infected or transfected cells (8). Interestingly, BTV-1 (D10905) NS4
was the only variant that failed to localize to the nucleoli of sheep
CPT-Tert cells (Fig. 7D), suggesting that nucleolar localization may
be critical for the activity of this nonstructural protein.
FIG 7 NS4 proteins from various BTV strains display inhibitory activity on gene expression. (A)Multiple-sequence alignment of representative NS4 sequences.
Identical residues compared to BTV8 (GenBank accession number JX680455) are shown as dots. The accession numbers refer to BTV genome segment 9
containing the NS4 open reading frame. (B) CPT-Tert cells were cotransfected with a plasmid expressing the indicated BTV NS4 protein (named according to
the accession number corresponding to BTV genome segment 9) and a plasmid expressing FLuc under the control of a CMVpromoter. FLuc activity was assessed
22 h posttransfection and in parallel byWestern blotting of the same cell lysates using anti-NS4 or anti--tubulin antibodies. One-way ANOVA, P
 0.0001. ***,
P
 0.001 (Dunnett’s multiple-comparison test). (C) CPT-Tert cells were cotransfected with increasing amounts of an expression plasmid for BTV8 NS4 and a
plasmid expressing FLuc under the control of the CMV immediate-early promoter. FLuc activity was assessed 22 h posttransfection in a luminometer and in
parallel by Western blotting of the same cell lysates using antibodies to NS4 or tubulin antibodies. One-way ANOVA, P
 0.0001. **, P
 0.01; ***, P
 0.001
(Dunnett’s multiple-comparison test). (D) Confocal microscopy of CPT-Tert cells transfected with pCI-NS4 plasmids. At 22 h posttransfection, the cells were
fixed and analyzed by immunofluorescence using antibodies against the nucleolarmarker B23 (red) andNS4 (green), with the appropriate conjugated secondary
antibodies as described in Materials and Methods. Scale bars, 33.21 	m. The error bars represent standard deviations.
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NS4 is not the only viral protein involved in host cell protein
shutoff. It is well established that BTV induces protein synthesis
shutoff in infected cells (64–66). Conceivably, a reduced level of
IFN (both mRNA and proteins) observed in cells infected with
BTV8wt could reflect the general virus-induced shutoff of protein
synthesis. In order to test this hypothesis, we metabolically radio-
labeled nascent proteins in ovEC mock infected or infected
with either BTV8wt or BTV8NS4. As expected, we observed de-
creased levels of 35S-labeled methionine/cysteine proteins in
BTV8wt-infected cells compared to mock-infected cells (particu-
larly evident at 18 and 26 h p.i.), confirming previously published
data (Fig. 8) (65, 66). Protein synthesis shutoff was also evident in
BTV8NS4-infected cells, although at somewhat reduced levels
compared to BTV8wt-infected cells. In order to quantify the re-
duction in protein synthesis during viral infection we used phos-
phorimaging and measured the signal intensity of a prominent
band present in all samples (Fig. 8A, black arrow). The signal
intensity of actin in BTV8wt-infected cells relative to mock-in-
fected cells (taken as 100%) decreased progressively to 69% at 10 h
p.i., 37% at 18 h p.i., and 2% at 24 h p.i., by which point cytopathic
effect was apparent. On the other hand, the signal intensity of
actin decreased to 82%, 56%, and 12%. Hence, these data suggest
that host protein shutoff induced by BTV occurs largely indepen-
dently of NS4, although the protein may contribute to the phe-
nomenon.
BTV-8NS4doesnot influencemRNAsplicingor translation.
We also assessed the impact of NS4 on RNA transcript splicing.
CPT-Tert cells were transfected with the pRL-CMV vector, which
is driven by the CMV immediate-early promoter and contains the
RLuc gene downstream of an intron. In this assay, NS4 retained
the ability to inhibit the expression of the reporter gene in a dose-
dependent manner (Fig. 8B), indicating that NS4 does not affect
mRNA splicing and confirming the data obtained by RNA-seq as
described above. Cells were also cotransfected with in vitro-tran-
scribed RNA encoding FLuc and an expression plasmid for BTV8
NS4, in order to determine whether NS4-induced inhibition of
protein expression could also occur at the translational level (Fig.
8C). Increasing levels of NS4 did not interfere with the level of
FLuc activity driven by RNA, as opposed to the activity driven by
plasmid DNA, used as a control, suggesting that the inhibition
mediated by NS4most likely occurs at the transcriptional and not
at the translational level.
FIG 8 NS4 expression does not significantly affect host cellular protein shut-
off, mRNA splicing, or translation. (A) Primary ovEC were mock infected or
infected with BTV8wt and BTV8NS4, and nascent proteins were metaboli-
cally labeledwith [35S]methionine/cysteine for 2 h at the time points indicated.
Cell extracts were fractionated by SDS-PAGE, and the gels were stained with
Coomassie blue. The dried gels were analyzed by phosphorimaging. The black
arrow indicates cellular actin. The signal intensity was quantified using
ImageQuant software. The red arrows indicate BTV proteins. (B) CPT-Tert
cells were cotransfected with variable amounts of plasmids expressing BTV8
NS4 protein and either a plasmid expressing FLuc under the control of a CMV
promoter or a plasmid expressing RLuc downstream of an intron and the
CMV promoter. FLuc or RLuc expression was assessed 22 h posttransfection.
Cell lysates were analyzed by Western blotting using antibodies to NS4. One-
way ANOVA, P 
 0.0001. **, P 
 0.01; ***, P 
 0.001 (Dunnett’s multiple-
comparison test). (C) CPT-Tert cells were cotransfected with variable
amounts of a DNA plasmid expressing BTV8 NS4 and either a plasmid ex-
pressing FLuc under the control of a CMV promoter or capped and polyade-
nylated RNA made in vitro. FLuc activity was assessed 22 h posttransfection.
Cell lysates were also analyzed by Western blotting using antibodies to NS4.
One-way ANOVA, P
 0.0001. *, P
 0.05; ***, P
 0.001 (Dunnett’s multi-
ple-comparison test). The error bars represent standard deviations.
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DISCUSSION
In this study, we showed that NS4 is an IFN antagonist and a
virulence factor for BTV. BTV NS4 deletion mutants replicate as
efficiently as wild-type viruses in cell lines that lack a competent
innate immune system and are lethal to IFNAR/ mice (8). In
contrast, here, we demonstrated that NS4 facilitates BTV replica-
tion in vitro in IFN-competent cells and in vivo in sheep, the ani-
mal species most affected by bluetongue.
BTV induces a type 1 IFN response in vivo and in vitro (38–42).
Our data strongly suggest that NS4 is required by the virus to help
overcome the cellular innate antiviral responses. Reporter assays
revealed thatNS4 can inhibit transcription froma variety ofmam-
malian and viral promoters while having little if any direct impact
on mRNA editing or translation. However, NS4 does appear to
influence the extent of the host IFN response, as supernatants of
primary sheep endothelial cells infected with BTV8NS4 con-
tained more IFN than supernatants collected from BTV8wt-in-
fected cells, a result that may explain the more efficient growth of
BTVwt in IFN-competent cells. These results were supported by
RNA-seq analyses of nascent RNA isolated from infected and
mock-infected cells. Genes relating to the innate immune system
were among the most upregulated genes in BTV8NS4-infected
cells, even if some of them were also found to be upregulated in
BTV8wt-infected cells, suggesting that NS4 is not by itself suffi-
cient to entirely inhibit the host IFN response. Most of the genes
that were specifically upregulated in BTV8NS4-infected cells
compared to BTV8wt-infected cells were ISGs, including those
encoding well-characterized antiviral factors.
Overall, the data obtained in this study indicate that NS4 exerts
its effect upon the antiviral host response at a point upstream of
RNA editing and translation. Interestingly, NS4 possesses features
of a transcription factor of the bZip family, with a basic domain
followed by a leucine zipper motif (67), and it has been suggested
to have the ability to bindDNA, based onDNase protection assays
(9). Our reporter assays, showing that NS4 inhibits transcription
from a variety of promoters, including IFN- and an ISRE-con-
taining promoter, suggest that the protein may inhibit cellular
transcription. In a previous study, we showed that NS4 displays
nucleolar localization in infected cells (8). Thus, a direct interac-
tion of NS4 with transcription factors and/or chromatin resulting
in the downregulation of cellular transcription is a possible mech-
anism of action for the protein. In support of this hypothesis, we
found that the NS4 protein of a BTV-1 strain that did not show
nucleolar localizationwas not able tomodulate gene expression in
reporter assays. It is also possible that NS4 inhibits IFN- activa-
tion before transcription. Nuclear translocation of IRF-3 and
NF-B appeared to occur at similar levels in both BTVwt- and
BTVNS4-infected cells, suggesting that NS4 does not prevent
PAMP recognition by host cells. However, it is possible that IRF-3
orNF-B could be inhibited byNS4 in the nucleus. It is important
to note that, in a previous study, we showed that NS4 confers a
replication advantage on BTV in cells pretreated with type I IFN,
highlighting its ability to counteract the innate immune response
after IFN activation. Hence, it is less likely that NS4 blocks PAMP
recognition and subsequent signaling. More studies will be neces-
sary to fully dissect how NS4 counteracts the host innate immune
system. Obviously, NS4, like other nonstructural proteins of dif-
ferent viruses, might have different functions and antagonize the
IFN response via multiple mechanisms. For example, the NS1
protein of influenzaA viruses inhibits IFNproduction by blocking
IRF3 and NF-B activation and mRNA maturation (68, 69).
It has been known for at least 3 decades that BTV induces host
protein synthesis shutdown (22, 64, 65). Recent studies suggest
that BTV NS1 favors viral RNA translation and therefore com-
peteswith cellular protein synthesis (22). A key difference between
mammalian and BTV transcripts is the lack of a poly(A) tail. The
NSP3 protein of rotaviruses (also members of the Reoviridae) acts
in a similar fashion and outcompetes the poly(A) binding protein
of cells, thus biasing translation of viral transcripts (70, 71). It
remains possible that a similarmechanismmay exist for BTV.Our
data, obtained in metabolically labeled cells, confirm that BTV
induces host protein synthesis shutdown and also establishes that
this occurs largely independently of NS4. Hence, other BTV pro-
teins might also play a similar role in the shutoff of host cell pro-
tein synthesis or function in different ways as IFN antagonists. For
example, NS3 is believed to modulate IFN induction downstream
of RIG-I and upstream of IKKε activation. Therefore, NS3 and
NS4 may potentially act synergistically to counteract the innate
immune system (28). In addition, it has also been shown that BTV
inhibits the IFN signaling pathway by downregulating key com-
ponents of the JAK/STAT pathway: JAK1 and TYK2 (43). The
downregulation of JAK1/TYK2 may be the result of a specific in-
teraction with a BTV protein and/or due to the general host pro-
tein synthesis shutdown induced by the virus. We did not find
either of the two genes to be differentially expressed inBTV8wt- or
BTV8NS4-infected cells.
In this study, we showed that BTV8NS4-infected sheep dis-
play lower levels of viremia, lasting for shorter periods, than the
viremia observed in animals infected with BTV8wt. The levels and
duration of viremia in infected animals are essential factors for
successful transmission between the mammalian hosts and the
intermediate arthropod vectors. As mentioned above, BTV infec-
tion can result in a lethal hemorrhagic fever in some animals,
while in others, the virus induces a mild febrile illness or even a
clinically unapparent infection. The data obtained in this study
provide evidence that viral proteins modulating the host innate
immune response play a significant role in viral pathogenesis. This
study lays the foundations for a deeper understanding of the
mechanisms by which BTV antagonizes the IFN system, in turn
helping us to define themolecular determinants of BTV virulence.
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